ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

Documenti analoghi

• ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
  di: Wilson, J, et al.
  Pubblicazione: (2017)
• A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
  di: Brunner, T, et al.
  Pubblicazione: (2008)
• A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
  di: Brunner, T, et al.
  Pubblicazione: (2008)
• Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
  di: Brunner, T, et al.
  Pubblicazione: (2008)
• HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
  di: Unaí Tupinambás, et al.